Biogen Resets Aduhelm Expectations, Expects Longer, Slower Path To Significant Sales

Best Case Scenario: Meaningful Patient Access Over Time

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The company reported $1m in Q4 sales of its Alzheimer’s drug. Biogen expects Aduhelm to make a minimal contribution to full-year 2022 revenues, which will total about $1bn less than in 2021. 

Autumn view of a long forest path
Biogen hopes to gain "meaningful patient access over time" from CMS • Source: Alamy

If the final decision from the US Centers for Medicare and Medicaid Services on covering Biogen, Inc.’s Aduhelm (aducanumab) and other amyloid-targeting therapies for Alzheimer’s disease does not improve from the draft national coverage determination (NCD) announced last month, Biogen will have to ramp up cost cuts it already has in the works and may reduce its revenue guidance further for 2022.

The $500m in planned cost cuts and the company’s full-year 2022 product revenue guidance of $9.7bn-$10bn assume that the final...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.